BATTERIES AND ELECTRODES FOR USE THEREOF
    21.
    发明申请
    BATTERIES AND ELECTRODES FOR USE THEREOF 审中-公开
    电池和电极用于其中

    公开(公告)号:US20090035664A1

    公开(公告)日:2009-02-05

    申请号:US12126841

    申请日:2008-05-23

    摘要: The present invention generally relates to batteries or other electrochemical devices, and systems and materials for use in these, including novel electrode materials and designs. In some embodiments, the present invention relates to small-scale batteries or microbatteries. For example, in one aspect of the invention, a battery may have a volume of no more than about 5 mm3, while having an energy density of at least about 400 W h/l. In some cases, the battery may include a electrode comprising a porous electroactive compound. In some embodiments, the pores of the porous electrode may be at least partially filled with a liquid such as a liquid electrolyte. The electrode may be able to withstand repeated charging and discharging. In some cases, the electrode may have a plurality of protrusions and/or a wall (which may surround the protrusions, if present); however, in other cases, there may be no protrusions or walls. The electrode may be formed from a unitary material. In certain embodiments, a nonporous electrolyte may be disposed onto the electrode. Such an electrolyte may allow ionic transport (e.g., of lithium ions) while preventing dendritic formation due to the lack of pores. In certain embodiments the porous electrode has a surface that is denser than its interior. Other aspects of the invention are directed to techniques of making such electrodes or batteries, techniques of forming electrical connections to and packaging such batteries, techniques of using such electrodes or batteries, or the like.

    摘要翻译: 本发明一般涉及电池或其他电化学装置,以及用于其中的系统和材料,包括新型电极材料和设计。 在一些实施例中,本发明涉及小型电池或微电池。 例如,在本发明的一个方面,电池的体积可以不大于约5mm 3,而能量密度为至少约400Wh / l。 在一些情况下,电池可以包括包含多孔电活性化合物的电极。 在一些实施方案中,多孔电极的孔可以至少部分地填充有诸如液体电解质的液体。 电极可以承受反复的充电和放电。 在一些情况下,电极可以具有多个突起和/或壁(如果存在则可以围绕突起); 然而,在其他情况下,可能没有突起或壁。 电极可以由整体材料形成。 在某些实施方案中,可以在电极上设置无孔电解质。 这样的电解质可以允许离子迁移(例如,锂离子),同时防止由于缺少孔而引起的树突状形成。 在某些实施例中,多孔电极具有比其内部更致密的表面。 本发明的其它方面涉及制造这种电极或电池的技术,形成与这种电池的电连接和包装的技术,使用这种电极或电池的技术等。

    Solid state forms of racemic ilaprazole
    22.
    发明授权
    Solid state forms of racemic ilaprazole 有权
    外消旋伊拉唑的固体形式

    公开(公告)号:US08592599B2

    公开(公告)日:2013-11-26

    申请号:US12939266

    申请日:2010-11-04

    IPC分类号: C07D401/12

    CPC分类号: C07D401/14

    摘要: The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl)1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.

    摘要翻译: 本发明涉及外消旋的伊拉唑,2 [[(4-甲氧基-3-甲基-2-吡啶基) - 甲基]亚磺酰基] -5-(1H-吡咯-1-基)1H-苯并咪唑的结晶形式。 本发明还涉及用于抑制胃酸分泌的药物组合物,其包含有效抑制胃酸分泌的量的本发明的伊拉唑结晶形式和药学上可接受的载体。 本发明还提供了治疗各种酸相关胃肠道(GI)障碍的方法。

    Crystalline forms of solvated ilaprazole
    24.
    发明授权
    Crystalline forms of solvated ilaprazole 失效
    溶剂化伊拉唑的结晶形式

    公开(公告)号:US07989632B2

    公开(公告)日:2011-08-02

    申请号:US11966896

    申请日:2007-12-28

    IPC分类号: C07D401/12

    CPC分类号: C07D401/14

    摘要: The invention relates to crystalline forms of various solvates of ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl)1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising crystalline ilaprazole hydrate according to the invention in an amount effective to inhibit gastric acid secretion and a pharmaceutically acceptable carrier. The invention also provides methods of treatment for various acid-related gastrointestinal (GI) disorders.

    摘要翻译: 本发明涉及伊拉帕唑,2 [[(4-甲氧基-3-甲基-2-吡啶基) - 甲基]亚磺酰基] -5-(1H-吡咯-1-基)1H-苯并咪唑的各种溶剂合物的结晶形式。 本发明还涉及用于抑制胃酸分泌的药物组合物,其包含有效抑制胃酸分泌的量的本发明的结晶伊拉拉唑水合物和药学上可接受的载体。 本发明还提供了治疗各种酸相关胃肠道(GI)障碍的方法。

    METHOD AND DEVICE FOR PACKET SCHEDULING
    25.
    发明申请
    METHOD AND DEVICE FOR PACKET SCHEDULING 审中-公开
    用于分组调度的方法和设备

    公开(公告)号:US20110158091A1

    公开(公告)日:2011-06-30

    申请号:US13000437

    申请日:2009-06-26

    IPC分类号: H04L12/56

    摘要: A method for packet scheduling is provided by the present invention. The method includes: A. buffering a received packet into a corresponding virtual output queue (VOQ) according to a class of service (CoS) and a destination contained in a header of the packet; B. generating a grant for each VOQ respectively according to the number of the packets in each VOQ and network congestion degree, and distributing the grant to the VOQ; C. performing packet scheduling and dequeuing by each VOQ according to the grant; and D. performing a round-robin scheduling according to the priority of the dequeued packet, and then scheduling and outputting the packet. A device for implementing packet scheduling is also provided by the present invention. The method and device can realize distributed scheduling on VOQs, enable flexible scheduling, and save the hardware logic resources.

    摘要翻译: 本发明提供一种分组调度方法。 该方法包括:根据业务类别(CoS)和包含在报文头中的目的地将接收的报文缓存到对应的虚拟输出队列(VOQ)中; B.根据每个VOQ中的分组数量和网络拥塞程度,分别为每个VOQ生成一个授权,并将该分配给VOQ; C.根据授权执行每个VOQ的分组调度和出队; 和D.根据出队分组的优先级进行循环调度,然后调度并输出分组。 本发明还提供了一种用于实现分组调度的设备。 该方法和设备可实现VOQ上的分布式调度,实现灵活调度,节省硬件逻辑资源。

    NOVEL FORMS OF REBOXETINE
    27.
    发明申请
    NOVEL FORMS OF REBOXETINE 审中-公开
    新形式的复方

    公开(公告)号:US20100069389A1

    公开(公告)日:2010-03-18

    申请号:US12553564

    申请日:2009-09-03

    CPC分类号: C07D265/30

    摘要: The invention relates to novel crystalline forms of (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine hydrochloride. In various embodiments, the novel crystalline forms may be substantially enantiopure. The preparation and characterization of the novel crystalline forms of (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine hydrochloride is also described. The invention also relates to pharmaceutical compositions containing novel crystalline forms of (2R)-2-[(R)-(2-ethoxyphenoxy)-phenylmethyl]morpholine hydrochloride, which are useful to treat and/or prevent various conditions such as nervous system and pain disorders.

    摘要翻译: 本发明涉及(2R)-2 - [(R) - (2-乙氧基苯氧基) - 苯基甲基]吗啉盐酸盐的新结晶形式。 在各种实施方案中,新的结晶形式可以是基本上对映体纯的。 还描述了(2R)-2 - [(R) - (2-乙氧基苯氧基) - 苯基甲基]吗啉盐酸盐的新结晶形式的制备和表征。 本发明还涉及包含(2R)-2 - [(R) - (2-乙氧基苯氧基) - 苯基甲基]吗啉盐酸盐的新结晶形式的药物组合物,其可用于治疗和/或预防各种病症如神经系统和 疼痛障碍